Alex Andrianopoulos
Chief R&D Officer @ Kairos Ventures
Pasadena, United States
Alex Andrianopoulos is a Series A investor at Kairos Ventures in Pasadena focused on Health Care and Biotechnology. Alex Andrianopoulos currently works as the Chief Research and Development Officer for Kairos Ventures. He previously worked at AtScale, Inc. as the Board of Advisors.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Alex Andrianopoulos invests in
Stages Alex Andrianopoulos invests in
Countries Alex Andrianopoulos invests in
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 2 (29%)
- Medical 1 (14%)
- Chemical 1 (14%)
- Software 1 (14%)
Stage
- Series A 3 (43%)
- Seed 2 (29%)
- Funding Round 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vivodyne
|
Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $40M / Series A / May 29, 2025 | |
|
Vivodyne
|
Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $38M / Seed / Nov 22, 2023 | |
Novosteo
|
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created aproprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces. | $5.5M / Series A / Jan 13, 2021 | |
Xidas
|
Xidas is a tech company producing the next-generation of micro-scale solutions for markets such as IoT, Industrial, and Life-tech. The company uses a new multi-patented miniaturization paradigm that combines unique manufacturing technologies, design methodologies, and diverse materials processing called Amalga to produce micro-scale solutions forindustrial, life-tech, and IoT applications that were once impossible.Xidas provides industry-first products and technologies to its industrial customers, leveraging a technology toolbox that includes precision manufacturing methods, micro-sensors, micro-actuators, 3D microstructures, and materials. It leverages its breakthrough patented technologies and multi-disciplinary expertise to design and produce highly integrated smart modules and sensors for deployment in a wide variety of IoT scenarios. | $6M / Series A / May 09, 2019 | |
Stoicheia
|
Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creatingstructures comprising up to seven elements. | $5M / Seed / Jan 27, 2019 | |
Siege Pharmaceuticals
|
Siege Pharmaceuticals develops cancer drugs based on a naturally occurring molecule that starves cancer cells to death. Its synthetic variants with optimized drug-like properties are based on a naturally occurring molecule and target multiple pathways that cancer cells need for growth, thereby enabling medical practitioners to control the growthand resistance of cancer cells from developing further. | Jan 01, 2019 | |
NVasc
|
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels inthe retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans. | Jan 01, 2019 |
Co-Investors
About Kairos Ventures
Kairos Ventures invests in ideas, patents, and businesses from the top universities and scientists. Kairos Venture Investments works to get science into the hands of applicable companies.Their team possesses an extraordinary passion to have a huge impact on our world through the creation of companies that will improve our lives and that of thegenerations that will follow. They aim to do this by backing the very best scientists, engineers and entrepreneurs and help them transform their knowledge, ideas and discoveries into viable businesses. They expect these companies to have a huge impact on the world and create significant returns for their shareholders.
Kairos Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alex Andrianopoulos
Chief R&D Officer
|
|||
Andreea Boier
Chief Talent Officer
|
|||
Carol Kachmer
VP, Accounting
|
|||
Danielle Walker
Investor Relations Manager
|
|||
DeeAnna Hampton
Executive Assistant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alex Andrianopoulos invest in?
Alex Andrianopoulos invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alex Andrianopoulos last invest?
The most recent investment recorded for Alex Andrianopoulos closed in May 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
